(VCEL) Vericel Ord - Overview
Stock: Cartilage, Skin, Burns, Therapy, Autologous
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 46.6% |
| Relative Tail Risk | -5.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.82 |
| Alpha | -59.19 |
| Character TTM | |
|---|---|
| Beta | 1.183 |
| Beta Downside | 0.774 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.72% |
| CAGR/Max DD | 0.15 |
Description: VCEL Vericel Ord January 15, 2026
Vericel Corporation (NASDAQ: VCEL) is a commercial-stage biopharma focused on autologous cellular therapies for sports-medicine cartilage repair and severe-burn treatment in North America.
The company’s flagship products are MACI (autologous cultured chondrocytes on a porcine collagen membrane for full-thickness knee cartilage defects), Epicel (a permanent skin-replacement device for deep-dermal and full-thickness burns), and NexoBrid (an enzymatic eschar-removal agent for partial- and full-thickness thermal burns.
In its most recent quarter (Q4 2023) Vericel reported $57 million in total revenue, a 22 % YoY increase driven primarily by MACI sales, while cash and short-term investments stood at $306 million, giving the firm roughly 14 months of runway at current burn-rate levels.
Key sector drivers include the aging-population-related rise in osteoarthritis cases, expanding insurance reimbursement for regenerative orthopaedic procedures, and a growing demand for advanced burn-care products amid higher incidence of severe injuries in both civilian and military settings.
For a deeper dive into Vericel’s valuation metrics and scenario analysis, you may find ValueRay’s research platform worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 13.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -0.35 > 1.0 |
| NWC/Revenue: 68.18% < 20% (prev 65.76%; Δ 2.42% < -1%) |
| CFO/TA 0.13 > 3% & CFO 59.1m > Net Income 13.1m |
| Net Debt (-2.40m) to EBITDA (23.8m): -0.10 < 3 |
| Current Ratio: 4.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.9m) vs 12m ago 5.75% < -2% |
| Gross Margin: 73.81% > 18% (prev 0.71%; Δ 7310 % > 0.5%) |
| Asset Turnover: 61.33% > 50% (prev 58.10%; Δ 3.23% > 0%) |
| Interest Coverage Ratio: 22.27 > 6 (EBITDA TTM 23.8m / Interest Expense TTM 622.0k) |
Altman Z'' 2.47
| A: 0.39 (Total Current Assets 222.0m - Total Current Liabilities 45.6m) / Total Assets 453.3m |
| B: -0.88 (Retained Earnings -399.5m / Total Assets 453.3m) |
| C: 0.03 (EBIT TTM 13.9m / Avg Total Assets 421.8m) |
| D: 2.45 (Book Value of Equity 321.9m / Total Liabilities 131.4m) |
| Altman-Z'' Score: 2.47 = A |
Beneish M -2.86
| DSRI: 1.09 (Receivables 60.4m/48.5m, Revenue 258.7m/226.8m) |
| GMI: 0.97 (GM 73.81% / 71.47%) |
| AQI: 1.21 (AQ_t 0.12 / AQ_t-1 0.10) |
| SGI: 1.14 (Revenue 258.7m / 226.8m) |
| TATA: -0.10 (NI 13.1m - CFO 59.1m) / TA 453.3m) |
| Beneish M-Score: -2.86 (Cap -4..+1) = A |
What is the price of VCEL shares?
Over the past week, the price has changed by +0.58%, over one month by -8.01%, over three months by -6.61% and over the past year by -39.38%.
Is VCEL a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VCEL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55 | 52% |
| Analysts Target Price | 55 | 52% |
| ValueRay Target Price | 34.3 | -5.3% |
VCEL Fundamental Data Overview February 03, 2026
P/E Forward = 49.2611
P/S = 7.0334
P/B = 5.7353
Revenue TTM = 258.7m USD
EBIT TTM = 13.9m USD
EBITDA TTM = 23.8m USD
Long Term Debt = 98.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.8m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.40m USD (from netDebt column, last quarter)
Enterprise Value = 1.78b USD (1.82b + Debt 98.0m - CCE 135.4m)
Interest Coverage Ratio = 22.27 (Ebit TTM 13.9m / Interest Expense TTM 622.0k)
EV/FCF = 41.72x (Enterprise Value 1.78b / FCF TTM 42.7m)
FCF Yield = 2.40% (FCF TTM 42.7m / Enterprise Value 1.78b)
FCF Margin = 16.51% (FCF TTM 42.7m / Revenue TTM 258.7m)
Net Margin = 5.06% (Net Income TTM 13.1m / Revenue TTM 258.7m)
Gross Margin = 73.81% ((Revenue TTM 258.7m - Cost of Revenue TTM 67.7m) / Revenue TTM)
Gross Margin QoQ = 73.46% (prev 73.71%)
Tobins Q-Ratio = 3.93 (Enterprise Value 1.78b / Total Assets 453.3m)
Interest Expense / Debt = 0.16% (Interest Expense 158.0k / Debt 98.0m)
Taxrate = 1.41% (148.0k / 10.5m)
NOPAT = 13.7m (EBIT 13.9m * (1 - 1.41%))
Current Ratio = 4.87 (Total Current Assets 222.0m / Total Current Liabilities 45.6m)
Debt / Equity = 0.30 (Debt 98.0m / totalStockholderEquity, last quarter 321.9m)
Debt / EBITDA = -0.10 (Net Debt -2.40m / EBITDA 23.8m)
Debt / FCF = -0.06 (Net Debt -2.40m / FCF TTM 42.7m)
Total Stockholder Equity = 304.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.10% (Net Income 13.1m / Total Assets 453.3m)
RoE = 4.30% (Net Income TTM 13.1m / Total Stockholder Equity 304.0m)
RoCE = 3.45% (EBIT 13.9m / Capital Employed (Equity 304.0m + L.T.Debt 98.0m))
RoIC = 4.49% (NOPAT 13.7m / Invested Capital 304.0m)
WACC = 9.75% (E(1.82b)/V(1.92b) * Re(10.27%) + D(98.0m)/V(1.92b) * Rd(0.16%) * (1-Tc(0.01)))
Discount Rate = 10.27% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.37%
[DCF Debug] Terminal Value 68.40% ; FCFF base≈40.9m ; Y1≈34.1m ; Y5≈25.1m
Fair Price DCF = 6.89 (EV 345.9m - Net Debt -2.40m = Equity 348.3m / Shares 50.6m; r=9.75% [WACC]; 5y FCF grow -20.07% → 2.90% )
EPS Correlation: 34.22 | EPS CAGR: 29.54% | SUE: -4.0 | # QB: 0
Revenue Correlation: 79.53 | Revenue CAGR: 9.77% | SUE: 1.92 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.58 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+123.1% | Growth Revenue=+18.6%